Psst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveCLEATUS Webinar: AI for Government Contracting — Free Webinar — Wednesday, October 28 at 2:00 PM ET

Register Free →

Search

Top

BIOCRYST PHARMACEUTICALS INC

UEI: MGXADJ6SCLJ5CAGE: 4GBX7

BIOCRYST PHARMACEUTICALS INC is a federal contractor, registered under UEI MGXADJ6SCLJ5 and CAGE code 4GBX7. It has been awarded $340,856,060 in federal contracts. Primary work spans Research and Development in the Physical, Engineering, and Life Sciences, Pharmaceutical Preparation Manufacturing, and Research and Development in Biotechnology. Top awarding agencies include Department Of Health And Human Services and Department Of Veterans Affairs.

Contact Information

Registration and classification details

Phone+1 (555) 000-0000

Websitewww.biocryst.com

Address123 Main St, City, ST 12345

Registration

UEI Code

MGXADJ6SCLJ5

CAGE Code

4GBX7

Entity Structure

Corporate Entity (Not Tax Exempt)

Established

N/A

Business Classifications

For Profit Organization

NAICS Codes

325412Pharmaceutical Preparation Manufacturing(Primary)

541714Research and Development in Biotechnology (except Nanobiotechnology)

Federal Contracting Overview

Award totals, agency breakdown, NAICS distribution, and geographic footprint.

AI Capability Profile

BIOCRYST PHARMACEUTICALS INC specializes in the manufacturing and supply of specialized pharmaceutical preparations, with deep expertise in the production of oral and injectable therapeutics for chronic and acute conditions. The company’s technical capabilities center on active pharmaceutical ingred...

Key Performance Metrics

Awards Count

29

All time

Active

0

Currently performing

Completed

29

Past period of performance

Total Awards

All time

Contracts

Prime · all time

Subcontracts

Sub · all time

Grants

Prime · all time

Subgrants

Sub · all time

Award Analytics & Distribution

Awards by Agency

Department Of Health And Human Services$338.4M99.3%Department Of Veterans Affairs$2.4M0.7%

Awards by NAICS

541710 - Research and Development in the Physical, Engineering, and Life Sciences$205.0M60.1%325412 - Pharmaceutical Preparation Manufacturing$73.5M21.6%541711 - Research and Development in Biotechnology$59.8M17.5%541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)$2.6M0.8%

Awards by Agency Over Time

Awards by Place of Performance

Compete with BIOCRYST PHARMACEUTICALS INC

Track the contractors you bid against, and the work they win

Award history, agency mix, and NAICS coverage for BIOCRYST PHARMACEUTICALS INC

AI-powered matching against your own capabilities and past performance

Teaming and subcontracting signals on every award

Automated alerts when a competitor wins in your market

Join 750+ contractors already using CLEATUS

Open opportunities in BIOCRYST PHARMACEUTICALS INC's top NAICS codes and agencies

U.S. Army Contracting Command – Watervliet Arsenal (ACC-WVA) Organic Industrial Base (OIB) Modernization Commercial Solutions Opening (CSO)

Solicitation # W911PT26SC001

The U.S. Army Contracting Command – Watervliet Arsenal (ACC-WVA) has issued solicitation W911PT26SC001, a Commercial Solutions Opening (CSO) authorized under the National Defense Authorization Act for Fiscal Year 2026 and DFARS Subpart 212.70. This competitive solicitation is open until September 30, 2027, and is designed to acquire innovative commercial products, technologies, and services to modernize the Army's Organic Industrial Base. The scope focuses on integrating manufacturing resources, linking legacy analogue systems with digital systems, and expanding modeling and simulation to enhance the delivery of materiel solutions. The CSO targets both traditional and non-traditional business entities, including small businesses and foreign-owned firms, provided they maintain an active System for Award Management (SAM) profile and a Unique Entity ID. The acquisition process follows a multi-phased approach consisting of a written solution brief, an optional presentation or pitch, and a final Request for Commercial Solution Proposal (CSP). Evaluation is based on responsiveness, technical merit, uniqueness, and price reasonableness. Successful responses may result in fixed-price contracts awarded under FAR Part 12 Commercial Item Procedures. Current Areas of Interest (AoIs) include advanced cannon technology, electrical infrastructure improvements at Building 120, chromium facility conversion, automated manufacturing for minor components, automated cooling tower treatments, advanced CNC vertical turning lathes, and advanced tooling for radial forging. Performance is primarily located at Watervliet Arsenal and Benet Laboratories, with a general period of performance not to exceed 12 months unless otherwise specified.

POSTED

about 19 hours ago

DEADLINE

"Provide specialized piping expertise overseeing the Craft Labor/Corrosion Control subcontractor for field modifications at KSC including but not limited to fabrication and installation of piping spool pieces, piping & tubing supports, flared & welded tub

Solicitation # 80NSSC26945986Q

NASA Shared Services Center

POSTED

about 19 hours ago

DEADLINE

Pralidoxime Chloride/Methyl Sulfate ManufacturingThis subcontract involves the manufacture and supply of Pralidoxime chloride or methyl sulfate in solution or powder form for injection to support prime contractors on Department of National Defence projects. The required product must have a dosage strength of at least 200 mg per container and a minimum shelf-life of 36 months. The selected provider is responsible for conducting stability testing, providing quality assurance certification, and delivering complete treatment courses along with stability reports and product monographs. To be eligible, the manufacturer must hold a Health Canada Notice of Compliance under Division 8 or Division 11 authorization. This global procurement opportunity is managed by the Government of Canada and allows for performance across various international regions. Interested parties must submit their responses by November 10, 2026.

Department of National Defence

POSTED

DEADLINE

SLS Printer Consumables and Maintenance KitsThis subcontract focuses on the provision of specialized consumables and wear-and-tear replacement parts to support prime contractors working on Department of National Defence projects for the Government of Canada. The scope of supply includes engineering-grade thermoplastic powders such as PA 11, PA 12, PP, and TPU, along with critical SLS hardware components including optical cassettes, recoater blades, infrared heaters, sealing foam gaskets, and build chambers. All bulk consumables and spare parts kits are to be delivered to CFB Petawawa. The opportunity was posted on October 20, 2026, with a response deadline of November 2, 2026, falling under NAICS code 325412.

Department of National Defence

POSTED

DEADLINE

Scientific Data Management and Publication SupportThe Scientific Data Management and Publication Support subcontract, issued by the National Institutes of Health under the Department of Health and Human Services, focuses on the dissemination of data, tools, and technologies for prime contractors involved in NIDCD medical research projects. The selected provider will manage resource sharing between laboratories and the NIDCD, assist in the preparation of scientific publications, and implement NIH Data Management and Sharing plans. These tasks must be executed using statistical software and secure data repositories while maintaining strict adherence to NIH cybersecurity guidelines. The primary deliverables for this engagement include the provision of disseminated data sets and the completion of published research papers. This opportunity falls under NAICS code 541715 and has a response deadline of March 5, 2027.

National Institutes Of Health

POSTED

DEADLINE

Human Temporal Bone and Fresh Ear Tissue Processing LaboratoryThis subcontract for the National Institutes of Health involves the receiving and processing of human temporal bones and fresh ear tissue to support research network projects for the NIDCD. The selected provider will be responsible for obtaining specimens from the National Hearing and Balance Organ Donor Program, processing inner and middle ear tissues, scanning slides, and summarizing donor medical records. Final deliverables include the processed specimens, high-resolution scanned images, and comprehensive annotated data. To execute these tasks, the contractor must possess specialized high-resolution slide scanning equipment and maintain strict biohazard containment protocols. Additionally, the provider is required to maintain an active IRB certification throughout the duration of the project. This effort falls under NAICS code 541715 and is managed under the Department of Health and Human Services.

National Institutes Of Health

POSTED

DEADLINE

in about 1 year

Coordinating Center for National Resource Network for the Study of Human Auditory and Vestibular Disorders (U24 Clinical Trial Not Allowed)

Solicitation # RFA-DC-28-002

Solicitation RFA-DC-28-002 is a Notice of Funding Opportunity from the National Institutes of Health, specifically the National Institute on Deafness and Other Communication Disorders, to establish a Coordinating Center for the NIDCD National Human Ear Resource Network. This collaborative network provides human inner and middle ear tissues to researchers for basic and clinical studies aimed at advancing the treatment of auditory and vestibular disorders. The Coordinating Center is responsible for maintaining network cohesiveness through the planning of workshops, symposia, and regular meetings, providing updates to laboratories, and managing communication with the public and scientific community regarding tissue donation. The maximum project period is five years, with a budget limit of 200,000 dollars in direct costs per year. Applicants, including for-profit organizations and small businesses, must maintain active registrations in SAM, eRA Commons, and Grants.gov. Proposals are evaluated based on the significance of the proposed center and the qualifications of the investigators, with additional reviews for human subject protections, inclusion policies, and the use of vertebrate animals. Key requirements include a structured Data Management and Sharing Plan and adherence to cybersecurity guidelines, including a 48-hour incident reporting window. The application process is entirely electronic and requires several standard PHS and SF424 forms, with a response deadline of March 5, 2027.

National Institutes Of Health

POSTED

DEADLINE

National Resource Network for the Study of Human Auditory and Vestibular Disorders (U24 Clinical Trial Not Allowed)

Solicitation # RFA-DC-28-001

Solicitation RFA-DC-28-001 is a Notice of Funding Opportunity issued by the National Institutes of Health under the Department of Health and Human Services to support the NIDCD National Human Ear Resource Network. The objective is to maintain a collaborative network of laboratories that serve as a national technological resource, providing human inner and middle ear tissues to researchers for basic and clinical studies to advance the treatment of auditory and vestibular disorders. The scope of work includes processing human temporal bones from the National Hearing and Balance Organ Donor Program, uploading images and medical data to EarBase, sharing gene-expression data via the gEAR repository, and providing technical instruction to increase the number of skilled researchers in the field. The NIDCD intends to commit 3.6 million dollars in FY 2028 to fund up to six awards, with a maximum project period of five years. Individual awards are limited to 450,000 dollars in direct costs per year, with an additional 150,000 dollars available for specific subawards. Applications are due on March 05, 2027, and November 01, 2027, with staggered start dates ranging from July 2027 to July 2028. Evaluation is based on the experience of the investigators, the adequacy of the institutional environment, and the protection of human subjects. Applicants must maintain active SAM registration and a Unique Entity Identifier, and they must provide a Data Management and Sharing Plan and a Material Transfer Agreement. Compliance with the Cybersecurity Act of 2015 is required, including the development of an incident response plan and notification of cybersecurity incidents within 48 hours of discovery.

National Institutes Of Health

POSTED

DEADLINE

in about 1 year

Silviculture Growth & Yield Modelling SpecialistThe Silviculture Growth and Yield Modelling Specialist subcontract supports prime contractors on projects for the Province of British Columbia's Ministry of Forests. The selected specialist will perform advanced statistical analysis and growth and yield modelling, specifically utilizing the Mixedwood Growth Model to establish stocking standards for conifer, broadleaf, mixedwood, and successional forests. A primary objective of the role is the creation of algorithms designed to project stand attributes based on data gathered from free growing surveys. Candidates must possess advanced proficiency in statistical analysis software and extensive expertise with the Mixedwood Growth Model to successfully deliver the required projection algorithms and modelled results. This opportunity was posted on October 19, 2026, with a response deadline of October 29, 2026.

Ministry of Forests

POSTED

DEADLINE

Supplier of Red Sealing Compound (NSN 8030015650423)This subcontract involves the supply of red sealing compound, identified by NSN 8030015650423, for prime contractors working under the Defense Logistics Agency. The material must be provided in 10.00 milliliter containers and strictly adhere to the DLA Master List of Technical and Quality Requirements RA001. The supplier is responsible for managing TYPE I (CODE H) shelf-life requirements and ensuring all packaging complies with MIL-STD-2073-1E and MIL-STD-129 standards. Additionally, the contractor must provide all necessary safety documentation, including SDS and HazCom labels in accordance with 29 C.F.R. 1910.1200. The performance of this contract is centered in FPO 09591-0100, with the primary objective being the delivery of packaged sealing compound and its associated safety certifications to the Department of Defense.

Defense Logistics Agency

POSTED

DEADLINE

Active Pharmaceutical Ingredient (API) SupplyThis subcontract for Active Pharmaceutical Ingredient (API) Supply involves the synthesis, purification, and bulk delivery of pharmaceutical-grade Benzocaine and Menthol. The provider supports prime contractors fulfilling requirements for the Department of Defense Medical Supply Chain Pharm FSA, ensuring all raw chemical components meet strict USP and ISO manufacturing standards through the use of HPLC purity testing. The performance of this contract is centered at Fort Campbell, Kentucky, under NAICS code 325412. The solicitation was posted on October 19, 2026, with a response deadline of October 26, 2026.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

Benzocaine and Menthol Lozenge SupplyThis subcontract involves the manufacture and supply of finished Benzocaine and Menthol lozenges to prime contractors supporting the Department of Defense Medical Supply Chain Pharm FSA. The provider is responsible for producing and quality-testing pharmaceutical lozenges within FDA-compliant facilities adhering to Good Manufacturing Practice standards to ensure all delivered quantities meet strict government specifications. Administrative processes for this requirement are managed through the DLA Internet Bid Board System for quote submissions. The performance of the contract is centered at Fort Campbell, and the procurement falls under NAICS code 325412 for pharmaceutical preparation.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

Supply of Moxifloxacin Hydrochloride Tablets (400 MG)This subcontract, managed by the Medical Supply Chain Pharm FSA under the Department of Defense, involves the manufacture and supply of pharmaceutical-grade Moxifloxacin Hydrochloride Tablets (400 MG). The contractor is responsible for providing the antibiotic tablets in 30-count bottles, ensuring all products are sourced or manufactured in accordance with Good Manufacturing Practices and FDA approval and registration requirements. Logistical compliance is critical, as the contract mandates adherence to RP001 DLA Packaging Requirements and the use of climate-controlled storage and transport to maintain product integrity. Performance will take place in FPO 09591, with the primary objective of supporting prime contractors on DLA supply contracts.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

Supply of Activated Charcoal, SuspensionThis subcontract, issued by the Medical Supply Chain Pharm FSA under the Department of Defense, requires the provision of activated charcoal in suspension form, identified by NSN 6505012828880. The materials must be delivered to the USS Lewis B Puller ESB 3, with all shipments adhering to strict DLA packaging requirements and technical specifications. The contract falls under NAICS code 325412 and is intended for prime contractors supporting DLA supply operations. Resellers are specifically required to comply with the Non-Manufacturer Rule to ensure eligibility. The performance location is designated as FPO 09591, with a response deadline set for October 26, 2026.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

Supply of 4% Chlorhexidine Gluconate Surgical DetergentThis subcontract involves the supply of FDA-regulated 4% Chlorhexidine Gluconate surgical detergent for prime contractors supporting Department of Defense supply contracts. The provider is responsible for manufacturing or sourcing the chemical compound in strict accordance with NSN 6505-01-101-3759 specifications and DLA Packaging Requirements RP001. To maintain quality and regulatory compliance, the product must be produced in FDA-approved pharmaceutical manufacturing facilities. The contract mandates a total shelf life of 24 months, with a requirement that the detergent possesses at least 21 months of remaining shelf life at the time of delivery. Managed under the Medical Supply Chain Pharm FSA, the performance of this contract is centered in FPO 96660, falling under NAICS code 325412.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

Supply of Bupivacaine and Epinephrine InjectionThis subcontract involves the supply of Bupivacaine and Epinephrine Injection to prime contractors supporting DLA Troop Support medical supply contracts. The provider must deliver end items compliant with NSN 6505-01-189-3973, utilizing pharmaceutical-grade materials and medical-grade packaging. To qualify, the supplier is required to hold all necessary pharmaceutical manufacturing licenses and maintain FDA approval for the specific drug formulation. Managed by the Department of Defense under the Medical Supply Chain Pharm FSA, the contract specifies the delivery of injectable medication quantities as outlined in the award. The performance location is designated as FPO 09591, and the procurement falls under NAICS code 325412.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

Isoniazid Tablet ManufacturingThis subcontract involves the manufacturing of Isoniazid 300 MG tablets for prime contractors supporting Department of Defense pharmaceutical supply contracts through the Medical Supply Chain Pharm FSA. The manufacturer is responsible for producing tablets that conform to United States Pharmacopeia standards, packaged in bottles of 100 units. To execute this contract, the provider must utilize pharmaceutical grade API, specialized tablet pressing equipment, and a USP-compliant quality control laboratory. Strict regulatory adherence is required, including the maintenance of active FDA registration and continuous USP compliance. The performance of this contract is centered in FPO 09591, with the primary objective of delivering finished pharmaceutical products that meet all specified government quality and safety benchmarks.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

Tetrahydrozoline Hydrochloride Ophthalmic Solution SupplierThis subcontract involves the supply of Tetrahydrozoline Hydrochloride Ophthalmic Solution, USP (0.05%, 15 ML) to support prime contractors under DLA Troop Support medical supply contracts. The selected provider is responsible for manufacturing or sourcing the pharmaceutical solution in accordance with USP standards, utilizing sterile ophthalmic bottling and packaging. All operations must comply with FDA approval and registration requirements for pharmaceutical manufacturing. The contract is managed by the Department of Defense under the Medical Supply Chain Pharm FSA. Physical deliveries of the ophthalmic solution are to be made to either the prime contractor or the Naval Med Readiness Logistics Command, with the place of performance located in Williamsburg, Virginia.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE